Dr. Djaballah has several years of industrial experience in early drug discovery gained over the years in pharma and biotech companies. He has extensive experiences in the areas of fluorescence technology, assay development, automation/robotics, HTS, compound & screening data management, software development & novel technologies. Dr Djaballah has been involved in developing and screening several targets in various therapeutic areas, including antibacterials, antivirals, antifungals, diabetes, CNS, cardiovascular, oncology & inflammation. He is currently the director of the high throughput drug screening core facility at Memorial Sloan Kettering Cancer Centre in New York. He obtained his BSc (Hons.) in biochemistry and biotechnology from the University of Birmingham, and his PhD in biochemistry from the University of Leicester, both in England.
RNAi Screening Come of Age: For the Love of my Target
Wednesday, 23 November 2011 at 09:00
Add to Calendar ▼2011-11-23 09:00:002011-11-23 10:00:00Europe/LondonRNAi Screening Come of Age: For the Love of my TargetRNAi Asia in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
RNAi screening has offered the premise of performing several thousand simultaneous knockdowns leading to the discovery and validation of existing and novel targets. Several years on, has the technology matured enough to keep up with its premise?
Add to Calendar ▼2011-11-22 00:00:002011-11-23 00:00:00Europe/LondonRNAi AsiaRNAi Asia in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2011-11-23 09:00:002011-11-23 10:00:00Europe/LondonRNAi Screening Come of Age: For the Love of my TargetRNAi Asia in SingaporeSingaporeSELECTBIOenquiries@selectbiosciences.com
